Biliary atresia (BA), a rare but serious cholestatic disorder in newborn infants, is caused by obstruction of extrahepatic or intrahepatic bile ducts with an occurrence rate of about 1/12,000 cases in United States and a higher incidence in Asia[@b1][@b2]. If not recognized and treated, BA will develop to progressive biliary cirrhosis and liver failure which could cause death within two years[@b3]. Kasai operation can reestablish bile flow in up to two-thirds of BA patients when performed earlier than 60 days of age[@b2]. However, a majority of patients will need liver transplant for survival if significant fibrosis and cirrhosis still exist after surgical intervention. Therefore, early identification and timely surgery are crucial for better prognosis. Unfortunately, definitive diagnosis of BA requires invasive and time-consuming diagnostic procedures, such as intra-operative cholangiogram and liver biopsy[@b4]. Consequently, it is urgently necessary for identification of noninvasive and convenient diagnostic biomarkers which may be helpful in distinguishing BA from the other neonatal cholestatic diseases.

MicroRNAs (miRNAs) are an abundant class of endogenous small and noncoding RNAs of about 22-nucleotides that post-transcriptionally regulate gene expressions[@b5]. Many studies have reported that miRNAs play important roles in experimental BA. The up-regulated expression of miR-29 in liver of murine BA model could lead to dysregulations of Igf1 and Il1RAP which are respectively responsible for cholangiocyte survival and modulation of inflammation[@b6]. In addition, miR-133a/b, miR-30b/c, miR-200a, miR-195, miR-365 and miR-320 have regulatory roles in pathogenesis of BA according to the miRNA expression profiles of extrahepatic bile ducts and gallbladder from murine BA model[@b7]. Shen *et al.* have reported that miR-222 was highly expressed in the extrahepatic bile ducts which might be responsible for liver fibrosis in the murine BA model[@b8]. The PI3K/Akt signaling pathway is activated in BA by elevated expression of miR-200b through suppressing FOG2, leading to increased growth and migration of human hepatic stallate cells[@b9]. Although understanding of BA pathogenesis has been improved, BA still remains to be a significant challenge and needs to be further investigated[@b10]. Therefore, it is of great importance to focus on the pathogenesis and diagnosis of BA.

Expression patterns of serum miRNAs can detect various diseases and distinguish similar disorders because serum levels of miRNAs are reproducible, stable and consistent among individuals of the same species[@b11][@b12]. What's more, circulating miRNAs have been proposed as novel noninvasive biomarkers with encouraging diagnostic utility of BA. Zahm *et al.* have analyzed the serum miRNA expression profiles of BA patients and controls with indeterminate cholestasis by Low Density Array (TaqMan^®^ Array Human MicroRNA A Cards) and they found miR-200b/429 have promising diagnostic clinical performance for BA[@b13]. However, only 134 of 375 miRNAs were detected in the study of Zahm *et al.* and information about the molecular mechanisms of BA and diagnostic utility of serum miRNAs remains insufficient.

In order to screen more differentially expressed miRNAs, human microRNA microarrays from Agilent Technologies containing probes for 1523 miRNAs were adopted in this current study,. Meanwhile, advanced bioinformatics analysis including prediction of target genes, identification of interaction relationships between target genes and functional enrichment analysis was also conducted for better understanding of the molecular mechanisms of BA. Moreover, the differentially expressed miRNAs were further validated in a larger and independent cohort of 45 infants with BA and 30 controls with non-BA neonatal cholestasis to find potential serum miRNA biomarkers.

Results
=======

Screening of differentially expressed miRNAs and clustering analysis
--------------------------------------------------------------------

The differentially expressed miRNAs between infants with BA and NC controls were screened using a human miRNA microarray. A total of 13 differentially expressed miRNAs were identified, including 11 down-regulated and 2 up-regulated miRNAs ([Table 1](#t1){ref-type="table"}). The serum expression levels of hsa-miR-1273 g-3p and hsa-miR-92a-3p were significantly increased in the infants with BA. Meanwhile, infants with BA had significantly lower expression levels of hsa-miR-1268a, hsa-miR-3911, hsa-miR-4689, hsa-miR-3196, hsa-miR-4429, hsa-miR-4327, hsa-miR-150-3p, hsa-miR-642b-3p, hsa-miR-1249, hsa-miR-3195 and hsa-miR-5195-3p. Furthermore, hierarchical clustering analysis indicated the serum samples of infants with BA could be well distinguished from NC controls according to the expression levels of these 13 differentially expressed miRNAs ([Fig. 1](#f1){ref-type="fig"}).

Functional and pathway enrichment analysis
------------------------------------------

The number of predicted target genes for hsa-miR-1268a, hsa-miR-3911, hsa-miR-4689, hsa-miR-3196, hsa-miR-4429, hsa-miR-4327, hsa-miR-150-3p, hsa-miR-642b-3p, hsa-miR-1249, hsa-miR-3195, hsa-miR-5195-3p, hsa-miR-92a-3p and hsa-miR-1273 g-3p was 15, 26, 24, 35, 182, 131, 115, 333, 9, 9, 183, 209 and 74, respectively ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

The functional enrichment analysis revealed that target genes of hsa-miR-150-3p (FOXO3 and SMAD5), hsa-miR-642b-3p (WT1, PROX1, NFYB, CBL and RB1), hsa-miR-4327 (CREBBP, SALL1 and SOX2), hsa-miR-5195-3p (SMAD3, SOX9 and CITED2), hsa-miR-4429 (CREB5 and TFAP2B) and hsa-miR-92a-3p (RNF4, SOX4 and HNF1B) were significantly related to the protein binding (FDR = 0.000126268), sequence-specific DNA binding transcription factor activity (FDR = 0.001452774), positive regulation of transcription, DNA-dependent (FDR = 0.004632587) and nucleus (FDR = 0.00852864) ([Table 2](#t2){ref-type="table"}). The ROCK1 and ANK3 respectively targeted by hsa-miR-4689 and hsa-miR-3911 were also involved with protein binding. Another target gene of hsa-miR-4689 (SGK1) and hsa-miR-3911 (PLCB1) were related to nucleus. The members of frizzled (FZD) family (FZD1, FZD2 and FZD3) and G protein-coupled receptors (such as GPR64 targeted by hsa-miR-1249) were related to G-protein coupled receptor activity (FDR = 0.000125237). Meanwhile, FZD1 and FZD2 which were respectively targeted by hsa-miR-642b-3p and hsa-miR-3196 were also involved with the positive regulation of transcription, DNA-dependent.

There were 29 significantly enriched pathways for the target genes ([Supplementary Table 2](#S1){ref-type="supplementary-material"}), and the top ten pathways are listed in the [Table 2](#t2){ref-type="table"}. The target genes of hsa-miR-642b-3p (such as PPM1A, PAK2, PTPRR, PPKACB and MAP2K6), hsa-miR-4429 (such as MAPK1, AKT3, CACNG2, PPM1B, RAP1A and RASA1), hsa-miR-92a-3p (such as RAP1B, MAP2K4, NLK, DUSP10 and CACNA1I) and hsa-miR-3196 (such as JUND) were significantly enriched in the MAPK signaling pathway (FDR = 0.016391713, [Table 3](#t3){ref-type="table"}). Meanwhile, MAPK1, AKT3 and IGF1R regulated by hsa-miR-4429 also participate in the Proteoglycans in cancer (FDR = 0.004268857), Rap1 signaling pathway (FDR = 0.018406673) and Ras signaling pathway (FDR = 0.024181237). Besides, ROCK1 targeted by hsa-miR-4689 and PLCB1 targeted by hsa-miR-3911 were significantly involved in Proteoglycans in cancer, and PLCB1 was Rap1 signaling pathway and Glutamatergic synapse (FDR = 0.022324586). Moreover, the target genes of hsa-miR-4327 (CREBBP and IGF1R), hsa-miR-4689 (SGK1), hsa-miR-150-3p (IGF1, PRKAA2 and FOXO3), hsa-miR-4429 (MAPK1, AKT3, IGF1R and PTEN) and hsa-miR-92a-3p (NLK, KLF2 and PTEN) were revealed to participate in FoxO signaling pathway (FDR = 0.036456906).

In the constructed regulatory network ([Fig. 2](#f2){ref-type="fig"}), PTEN was simultaneously targeted by hsa-miR-92a-3p, hsa-miR-4429 and hsa-miR-642b-3p. The MAPK1 had the highest degree of 18 in the PPI network, followed by SMAD3 (degree = 12) and CBL (degree = 9) ([Fig. 3](#f3){ref-type="fig"}, [Table 4](#t4){ref-type="table"}). Moreover, PTEN was interacted with IGF1R, PXN, CBL and PPP3CA in the PPI network.

Validation of important miRNAs and enrichment analysis
------------------------------------------------------

Eight differentially expressed miRNAs (hsa-miR-92a-3p, hsa-miR-3911, hsa-miR-4689, hsa-miR-3196, hsa-miR-4429, hsa-miR-150-3p, hsa-miR-642b-3p and hsa-miR-1249) whose target genes were significantly enriched in important functions and pathways were selected as putative biomarkers for further validation. The expression levels of these eight candidate miRNAs were firstly measured by qRT-PCR in an independent cohort of serum samples from 10 infants with BA and 10 NC controls. The qRT-PCR revealed that hsa-miR-92a-3p and hsa-miR-4429 were respectively up-regulated and down-regulated with significant differences, showed the same change patterns as shown in with microarray analysis. However, the expression levels of hsa-miR-4689 (fold change = 2.36) and hsa-miR-150-3p (fold change = 4.08) were significantly increased which were opposite to the microarray analysis ([Fig. 4](#f4){ref-type="fig"}). This discrepancy between first screening and validation might be due to technical limitations of microarray, such as cross-hybridizations, signal saturations and limited dynamic range[@b14]. The other four miRNAs were excluded for further analysis since no significant differences were detected.

The functional enrichment analysis indicated that target genes of hsa-miR-150-3p (FOXO3 and SMAD5), hsa-miR-4429 (CREB5 and TFAP2B), hsa-miR-4689 (ROCK1) and hsa-miR-92a-3p (RNF4, SOX4 and HNF1B) were significantly related to the protein binding (FDR = 0.015416) ([Table 5](#t5){ref-type="table"}). The GNAI1 targeted by hsa-miR-4429 and GPR180 by hsa-miR-92a-3p were significantly related to the function of G-protein coupled receptor signaling pathway (FDR = 4.92E-05). A totoal of 14 significant pathways were enriched for the target genes of hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p ([Table 6](#t6){ref-type="table"}). There were 12 target genes (AKT3, CPD, FOXO3, IGF1, IGF1R, KLF2, MAPK1, NLK, NRAS, PRKAA2, PTEN and SGK1) that revealed to participate in FoxO signaling pathway (FDR = 0.007496). Meanwhile, target genes of hsa-miR-150-3p (IGF1 and PRKAA2), hsa-miR-4429 (AKT3, MAPK1, PTEN and TSC1), hsa-miR-92a-3p (TSC1 and PTEN) were simultaneously involved in the mTOR signaling pathway (FDR = 0.012814) and PI3K-Akt signaling pathway (FDR = 0.020308).

Diagnostic utility of potential miRNAs
--------------------------------------

The hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p were selected for subsequent analysis of diagnostic utility. The expression levels of these miRNAs were detected by qRT-PCR using serum samples from another 35 infants with BA and 20 NC controls. Significantly down-regulated expression levels of hsa-miR-4429 were observed in serum samples of infants with BA in comparison to NC controls (P = 0.006119, [Fig. 5B](#f5){ref-type="fig"}). The serum expression levels of hsa-miR-4689 were obviously higher in infants with BA (P = 0.040098, [Fig. 5C](#f5){ref-type="fig"}). However, there was no significant differences in the expression levels of hsa-miR-150-3p (P = 0.052556) and hsa-miR-92a-3p (P = 0.619144) ([Fig. 5A,D](#f5){ref-type="fig"}). After constructing ROC curves, the cutoff value for hsa-miR-4429 was 28.7112, with a sensitivity of 83.33% and a specificity of 80.00%. At the cutoff value of 0.1388 for hsa-miR-4689, the sensitivity was 66.67% and the specificity was 80.00%. The AUC was 0.789 (95% CI, 0.590--0.921) and 0.722 (95% CI, 0.518--0.876) for hsa-miR-4429 and hsa-miR-4689, respectively ([Fig. 6](#f6){ref-type="fig"}).

Discussion
==========

Long-term survival can be achieved without liver transplantation when the Kasai procedure is conducted within the first 30--45 days of life[@b15]. Since early diagnosis and convenient screening means of BA haven't been well established, treatment for BA is inadequate due to delayed diagnosis and poor understanding of the pathogenesis. In this study, 13 differentially expressed miRNAs were identified using the Agilent miRNA microarray expression profiling. Moreover, eight differentially expressed miRNAs were selected for validation by qRT-PCR using an independent serum samples from infants with BA and NC controls. The validation analysis revealed that four miRNAs including hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p were differentially expressed.

In our study, functional enrichment analysis indicated that GNAI1 targeted by hsa-miR-4429 and GPR180 by hsa-miR-92a-3p were significantly related to the function of G-protein coupled receptor signaling pathway. It has been revealed that secretin can contribute to increased ductular choleresis after stimulation of G-protein-coupled receptor and cAMP/protein kinase A (PKA)-dependent signalling pathway[@b16]. Moreover, decreased expression of the type III InsP3R in the cholangiocytes of patients with biliary atresia is associated with impaired Ca2+ signaling and messenger molecule interacts with specific G protein-coupled receptors can induce activation of phospholipase C and formation of InsP3 to increase Ca[@b2]+ [@b17][@b18]. Accordingly, hsa-miR-4429 and hsa-miR-92a-3p may be important for BA by targeting GNAI1 and GPR180 to influence the G-protein coupled receptor signaling pathway.

Moreover, target genes of hsa-miR-150-3p (IGF1, PRKAA2 and FOXO3), hsa-miR-4689 (SGK1), hsa-miR-4429 (MAPK1, AKT3, IGF1R and PTEN) and hsa-miR-92a-3p (NLK, KLF2 and PTEN) were significantly enriched in FoxO signaling pathway. BA is manifested by progressive inflammation and fibrosis of extrahepatic and intrahepatic bile ducts which can lead to cirrhosis[@b19]. It has been reported the FoxO3/Bim signaling pathway was obviously activated in patients with primary biliary cirrhosis[@b20]. Meanwhile, target genes of hsa-miR-4429 (AKT3, MAPK1, PTEN and TSC1) were significantly involved in the mTOR and PI3K-Akt signaling pathway. Increased expression levels of miR-200b in biliary atresia patients can acitvate PI3K/Akt signaling to accelerate migration and proliferation of hepatic stallate cells[@b9]. It has been reported that cystic proliferation of cholangiocytes of the polycystic kidney rat is associated with activation of the PI3K/mTOR pathway[@b21]. Therefore, it could be speculated thathsa-miR-4429 and hsa-miR-4689 might play important roles in BA by regulating their target genes that participate in these important signaling pathways.

Furthermore, the diagnostic utility of these four miRNAs (hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p) were analyzed in a larger independent sample set from another 35 infants with BA and 20 NC controls. The AUC of hsa-miR-4429 and hsa-miR-4689 was respectively 0.789 (95% CI, 0.590--0.921; sensitivity = 83.33%, specificity = 80.00%) and 0.722 (95% CI, 0.518--0.876; sensitivity = 66.67%, specificity = 80.00%), suggesting hsa-miR-4429 and hsa-miR-4689 might have the potential to be used as diagnostic biomarkers of BA. The human serum samples in the study of Zahm *et al.* were obtained from the Childhood Liver Disease Research and Education Network's prospective longitudinal study of cholestasis in infancy, and the results revealed that miR-200b/429 might has promising diagnostic performance with the AUC values greater than 0.80[@b13]. However, the expression levels of miR-200b/429 didn't significantly altered in the serum samples of infants with type III BA aged less than 90 days enrolled from the Children's Hospital of Fudan University in our study. It could be speculated the different results might be due to that samples obtained from different sources were investigated. However, there are some limitations in our study. Some characteristics of participates, such as ethnic and region, were not considered due to the limited sample size. Besides, the expression levels of import target genes were not studied.

In conclusion, the differentially expressed miRNAs (especially hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p) might play important roles in the pathogenesis of BA by regulating their target genes. Furthermore, hsa-miR-4429 and hsa-miR-4689 might have promising diagnostic performance for BA. In our next study, expression levels of important target genes will be investigated by integrated miRNA and mRNA analysis to find more potential biomarkers for BA.

Methods
=======

Study population and sample collection
--------------------------------------

In our study, 45 infants with BA and 30 infants with non-BA neonatal cholestasis (NC) similar in age and sex distribution during the same time period were enrolled from the Children's Hospital of Fudan University ([Table 7](#t7){ref-type="table"}). These participants were enrolled based on the diagnoses of operative cholangiogram and liver pathology. The inclusion criteria for infants with BA were as follows: aged less than 90 days; type III BA according to the classification of BA phenotype[@b22]; serum direct or conjugated hyperbilirubinemia (\>20% of total bilirubin and \>2 mg/dL). Infants were excluded when they had liver failure, malignancy, ischemic hepatopathy, hypoxia or shock within the preceding 2 weeks; treated with extracorporeal membrane oxygenation--associated cholestasis or prior hepatobiliary surgery. Meanwhile, infants with birth weight less than 1500 g, drug- or total parenteral nutrition-associated cholestasis, bacterial or fungal sepsis, or primary hemolytic disease were also excluded unless they were diagnosed with BA or another cholestatic disease definitively[@b23][@b24].

Blood samples were collected from these participants within a few days of enrollment preoperatively when the parents had given voluntary informed consent for their children. Our studies have been reviewed and approved by the ethics committee of the Children's Hospital of Fudan University and all the experiments were carried out in accordance with relevant guidelines and regulations.

Sample processing and total RNA isolation
-----------------------------------------

All whole blood samples collected from each participant were allowed to stand for about 1 h at room temperature. Then, these whole blood samples were separated into serum by centrifugation at 820 × g for 10 min at 4 °C, followed by further centrifugation at 16,000 × g for 10 min at 4 °C to completely remove cell debris. The supernatant serum was stored at −20 °C until analysis. Total RNA was isolated from 400 μl serum sample by using mirVana miRNA isolation kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. The concentration and quality of total RNA were monitored by NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and Agilent's 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).

Serum miRNA expression profiling and microarray analysis
--------------------------------------------------------

Serum samples of 4 infants with BA and 4 NC controls were used for miRNA microarray analysis. Human miRNA microarrays from Agilent Technologies (8\*60 K), containing probes for 1523 human miRNAs from the Sanger miRbase V18.0 database (<http://www.sanger.ac.uk/Software/> Rfam/ mirna), were adopted. Total RNA (100 ng) extracted from each serum sample was used as inputs for sample labeling and hybridization preparation in accordance with the manufacturer's protocol (Agilent Technologies, Santa Clara, CA).

The microarray image information was converted into spot intensity values using Scanner Control Software Rev. 7.0 (Agilent Technologies, Santa Clara, CA). The signal after background subtraction was exported directly into the GeneSpring GX version 12.5 software (Agilent Technologies, Santa Clara, CA) for quartile normalization. Then, differentially expressed miRNAs in serum were identified using the paired *t*-test with the cut-off criteria of P \< 0.05 and \|fold change\|\>1.5. In order to ensure the screened differentially expressed miRNAs were accurately identified, hierarchical clustering analysis of samples was employed using heatmap.2 function of th gplots package in R[@b25] based on the expression values.

The target genes of differentially expressed miRNAs were predicted by at least two databases of the following five usual prediction databases: TargetScan (<http://www.targetscan.org>), miRanda (<http://www.microrna.org/microrna/home.do>), PicTar (<http://pictar.mdc-berlin.de/>), MirTarget2 from miRDB (<http://mirdb.org/miRDB/download.html>) and PITA (<http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html>). Moreover, the Gene Ontology (GO) functional and pathway enrichment analysis were conducted for the target genes using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tools[@b26] with the cut-off criterion of false discovery rate (FDR) \< 0.05. The GO terms were identified in biological process (BP), cellular component (CC) and molecular function (MF) categories. The regulatory relationships for targets genes that simultaneously involved in significantly enriched functions and pathways were selected to constructe miRNA-target gene regulatory network. Protein-protein interactions (PPIs) for these target genes were revealed by the genemania (<http://www.genemania.org/>). The miRNA-target gene regulatory network and PPI network were both visualized using Cytoscape (Version 3.1.1)[@b27].

Quantitative real-time PCR (qRT-PCR)
------------------------------------

The relative quantification of selected differentially expressed miRNAs was performed by qRT-PCR reaction with the miScript SYBR Green PCR Kit (Qiagen) using ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The miRNA specific primers were designed by Primer Express software (Version 2.0, Applied Biosystems) based on the miRNA sequences obtained from miRbase database (<http://microrna.sanger.ac.uk/>). Primer sequences are listed in the [Table 8](#t8){ref-type="table"}.

Extracted total RNA (60 ng) from serum samples was reverse transcribed into cDNA using miScript Reverse Transcription Kit (Qiagen). Each reaction was performed in a 20 μl volume system containing 1.5 μl cDNA, 2 μl of each primer and 1 × QuantiTect SYBR Green PCR Master Mix (Qiagen). MiR-1228 was used as a stable endogenous control for normalization since it functions as a housekeeping gene according to the study of Hu *et al.*[@b28]. All reactions were carried out in triplicate. The relative expression levels of miRNAs were calculated by the 2^−△△Ct^ method.

Statistics
----------

Receiver-operating characteristic (ROC) curve analysis was performed to determine the specificity and sensitivity of miRNA as a diagnostic biomarker. MedCalc (version 10.4.7.0; MedCalc, Mariakerke, Belgium) software was adopted to perform ROC analysis. Area under the ROC curve (AUC) was calculated as an accuracy index for evaluating the diagnostic performance of selected miRNA. The 95% confidence interval (CI) was used to reflect statistical significance.
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![Hierarchical clustering analysis for the selected differentially expressed miRNAs.\
The horizontal axis represents the serum samples from infants with biliary atresia (BA) (S139, S134, S138 and S137) and non-BA neonatal cholestasis (NC) controls (S207, S206, S204 and S208). The miRNA names are shown on the left vertical axis. Colored bars indicate the range of fold changes.](srep21084-f1){#f1}

![The regulatory network for differentially expressed miRNAs.\
The blue nodes represent the target genes. The yellow triangles indicate differentially expressed miRNAs with the size corresponding to degree. The blue lines show the potential regulatory relationships between miRNAs and genes.](srep21084-f2){#f2}

![Protein-protein interaction (PPI) network for the predicted target genes of differentially expressed miRNAs.\
Colored bars indicate the degree of genes.](srep21084-f3){#f3}

![Validation of selected miRNAs by qRT-PCR.\
Serum expression levels of hsa-miR-92a-3p, hsa-miR-3911, hsa-miR-4689, hsa-miR-3196, hsa-miR-4429, hsa-miR-150-3p, hsa-miR-642b-3p and hsa-miR-1249 were measured in 10 infants with BA and 10 NC controls.](srep21084-f4){#f4}

![The expression levels of hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p in an independent set of serum samples from infants with BA (n = 35) and NC controls (n = 20) (**A**) hsa-miR-150-3p; (**B**) hsa-miR-4429; (**C**) hsa-miR-4689; (**D**) hsa-miR-92a-3p).](srep21084-f5){#f5}

![Receiver operating characteristic curve analysis for BA diagnosis (**A**) hsa-miR-4429, (**B**) hsa-miR-4689; AUC: area under the curve).](srep21084-f6){#f6}

###### The screened differentially expressed miRNAs in the serum samples of infants with biliary atresia.

  MiRNAs                  Name         Fold change   P value
  ---------------- ------------------ ------------- ----------
  Down-regulated     hsa-miR-1268a      −1.52824     0.031041
                      hsa-miR-3911      −1.64985     0.014516
                      hsa-miR-4689      −1.65676     0.015478
                      hsa-miR-3196      −1.68217     0.043657
                      hsa-miR-4429      −1.72581     0.042748
                      hsa-miR-4327      −1.75703     0.026081
                     hsa-miR-150-3p     −2.03072     0.002125
                    hsa-miR-642b-3p     −2.10194     0.01667
                      hsa-miR-1249      −2.16191     0.039503
                      hsa-miR-3195      −2.23659     0.034854
                    hsa-miR-5195-3p     −2.45733     0.005206
  Up-regulated       hsa-miR-92a-3p     1.528466     0.011198
                    hsa-miR-1273g-3p    2.342245     0.039625

###### The enriched Gene Ontology (GO) terms in molecular function (MF), biological process (BP) and cellular component (CC) categories for target genes of all the 13 differentially expressed miRNAs.

  GO_ID                                       GO_term                                  Category   Count                                                       Target Genes                                                           FDR
  ------------ ---------------------------------------------------------------------- ---------- ------- ---------------------------------------------------------------------------------------------------------------------- -------------
  GO:0005515                              Protein binding                                 MF       433              FZD1, FZD3, IGF1R, CBL, CREBBP, FOXO3, SMAD3, SMAD5, RB1, SALL1, SOX2, SOX4, TFAP2B, WT1, CREB5              0.000126268
  GO:0004930                    G-protein coupled receptor activity                       MF       11                         FZD2, LPAR4, GPR34, FZD3, FZD1, GPR64, GPR75, GPR126, ELTD1, GPR115, TAS2R20                       0.000125237
  GO:0003700        Sequence-specific DNA binding transcription factor activity           MF       100      CBL, CREBBP, CREM, ELK4, FOXO3, GABPB1, SMAD3, SMAD5, SMAD7, PROX1, RB1, SALL1, SOX2, SOX4,TFAP2B,WT1, CREB5...      0.001452774
  GO:0001105            RNA polymerase II transcription coactivator activity              MF        8                                  CREBBP, POU3F1, SOX4, SOX11, TFAP2B, CITED2, ANKRD1, HIPK2                                0.049058312
  GO:0045893            Positive regulation of transcription, DNA-dependent               BP       61     FZD1, FZD2, CREBBP, SMAD3, SMAD5, NFYB, PROX1, RB1, RNF4, SALL1, SOX2, SOX4, SOX9, HNF1B, TFAP2B, WT1, CREB5, CITED2   0.004632587
  GO:0006351                        Transcription, DNA-dependent                          BP       170        CREM, ELK4, GABPB1, GATA2, HIC1, HOXA5, JUND, SMAD3, SMAD5, SMAD7, MTF1, NFYB, PBX1, RB1, RNF4, SALL1, SOX2        0.004014426
  GO:0045944    Positive regulation of transcription from RNA polymerase II promoter      BP       77               JUND, SMAD3, SMAD5, SMAD7, MTF1, PBX1, PROX1, RB1, RNF4, SALL1, SOX2, SOX4, SOX9, HNF1B, TFAP2B,             0.006415167
  GO:0007156                          Homophilic cell adhesion                            BP       25                             CDH2, CDH10, DSC2, PCDH7, ROBO2, MPZL2, NPTN, PCDH11X, CDH20, PCDH18                           0.008450129
  GO:0005634                                  Nucleus                                     CC       396                 CBL, CREBBP, SMAD3, SMAD5, RB1, RNF4, SALL1, SOX2, SOX9, HNF1B, ZEB1, TFAP2B, WT1, CREB5,                 0.00852864
  GO:0005576                            Extracellular region                              CC       56                ADM, ANGPT2, COL1A2, EREG, FBN1, IGF1, IGSF1, KITLG, NOTCH3, YBX1, LRP8, ADAM12, NRP1, CD200R1              0.009038887
  GO:0005883                               Neurofilament                                  CC        6                                             NEFM, NEFH, NEFL, NRP1, INA, DLGAP2                                            0.017283848

FDR: false discovery rate.

###### The top ten enriched pathways for target genes of all the 13 differentially expressed miRNAs.

  Pathway_ID                             Name                            Count                                                      Target Genes                                                           FDR
  ------------ -------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------- -------------
  hsa04740                      Olfactory transduction                     5                                             CALM1, ADCY3, PRKX, PRKACB, ADRBK2                                            0.001989049
  hsa05205                     Proteoglycans in cancer                    31      ITGAV, ITGA5, IGF1, FRS2, CAV2, PIK3R3, MAPK1, PLCE1, GAB1, ITPR1, AKT3, ACTB, IGF1R, IQGAP1, FZD3, PRKACB, ROCK1    0.004268857
  hsa04010                      MAPK signaling pathway                    32     PPM1A, RAP1B, MAPK1, CACNG2, MAP4K4, AKT3, NLK, DUSP10, PTPRR, RASA1, MAP2K4, PPM1B, RAP1A, PRKACB, CACNA1I, MAP2K6   0.016391713
  hsa05414                      Dilated cardiomyopathy                    15         ACTG1, ITGB8, ITGAV, DAG1, ITGA5, IGF1, CACNA1D, ATP2A2, CACNG2, ADCY3, ACTB, PRKX, CACNA2D4, PRKACB, TPM3        0.02136154
  hsa04015                      Rap1 signaling pathway                    27         CNR1, MLLT4, FLT1, IGF1, GNAI1, CALM1, RAP1B, ANGPT1, PIK3R3, MAPK1, PLCE1, LPAR4, AKT3, ADCY3, ACTB, IGF1R       0.018406673
  hsa04520                        Adherens junction                       13                   ACTG1, CREBBP, MLLT4, YES1, LMO7, WASL, MAPK1, NLK, ACTB, IGF1R, SMAD3, TGFBR2, IQGAP1                  0.016409495
  hsa05412      Arrhythmogenic right ventricular cardiomyopathy (ARVC)    13                 ACTG1, CDH2, ITGB8, ITGAV, DAG1, ITGA5, DSC2, CACNA1D, PKP2, ATP2A2, CACNG2, ACTB, CACNA2D4               0.016093657
  hsa04724                      Glutamatergic synapse                     17                   GRIK5, GNAI1, CACNA1D, SLC1A2, MAPK1, ITPR1, PPP3CA, ADCY3, SLC17A6, DLGAP1, GNG7, PRKX                 0.022324586
  hsa04360                          Axon guidance                         18                      NRAS, DCC, SEMA6D, SRGAP1, SEMA3A, SEMA6A, PAK7, GNAI1, NRP1, MAPK1, ROBO2, PAK2                     0.02165145
  hsa04014                      Ras signaling pathway                     27                IGF1, CALM1, RAP1B, ANGPT1, PIK3R3, MAPK1, PLCE1, ARF6, GAB1, AKT3, IGF1R, PAK2, FGF23, GNG7               0.024181237

###### The target genes with degrees not less than five in the protein-protein interaction network.

  Target genes    Degree
  -------------- --------
  MAPK1             18
  SMAD3             12
  CBL               9
  PXN               8
  IQGAP1            8
  FOXO3             7
  CREBBP            7
  SMAD7             6
  JUND              6
  RASA1             6
  IGF1R             6
  CNOT7             5
  FBXW11            5
  ACTB              5
  TGFBR2            5
  CDK6              5

###### The enriched GO terms for target genes of hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p.

  GO_ID                                                                                   GO_term                                                                              Category   Count                                                         Target Genes                                                            FDR
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ------- --------------------------------------------------------------------------------------------------------------------------- ----------
  GO:0001077    RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription      MF       15                  KLF5, GATA2, MYB, NFIA, PBX1, SOX4, TCF21, TFAP2B, BTG2, KLF4, ONECUT2, CREB5, EHF, RIT1, MYOCD                0.012047
  GO:0005515                                                                          Protein binding                                                                             MF       232          FOXO3, SMAD5, CREB5, KLF5, RNF4, HNF1B, ROCK1, GATA2, MYB, PBX1, SOX4, TFAP2B, BTG2, KLF4, CREB5, RIT1, MYOCD         0.015416
  GO:0007156                                                  Homophilic cell adhesion via plasma membrane adhesion molecules                                                     BP       22              CDH2, CDH10, DSC2, ROBO2, NPTN, PCDH11X, CDH20, PCDHAC2, PCDHAC1, PCDHA13, PCDHA12, PCDH19, PCDH11Y...             8.62E-07
  GO:0007186                                                            G-protein coupled receptor signaling pathway                                                              BP        2                                                           GNAI1, GPR180                                                         4.92E-05
  GO:0045944                                                Positive regulation of transcription from RNA polymerase II promoter                                                  BP       50     ATRX, KLF5, CCNC, CUX1, DDX3X, ESRRG, FOXO3, GATA2, HOXA5, IGF1, SMAD7, PPP1R12A, NFIA, NPAS2, PAX9, RNF4, SOX4, DHX36...   0.00105
  GO:0017148                                                                 Negative regulation of translation                                                                   BP        9                                  DDX3X, TSC1, BTG2, FXR1, TOB1, SYNCRIP, IGF2BP3, CPEB3, NANOS1                                 0.002412
  GO:0033693                                                                   Neurofilament bundle assembly                                                                      BP        3                                                         NEFM, NEFH, NEFL                                                        0.012468
  GO:0018107                                                                 Peptidyl-threonine phosphorylation                                                                   BP        7                                           DYRK1A, MAPK1, TNKS, OXSR1, HIPK3, NLK, WNK1                                          0.014844
  GO:0005883                                                                           Neurofilament                                                                              CC        6                                                NEFM, NEFH, NEFL, NRP1, INA, DLGAP2                                              0.000132
  GO:0005730                                                                             Nucleolus                                                                                CC       74      HNF1B, TDG, TEAD1, NR2C2, FXR1, DYRK2, CGGBP1, TNKS, BAZ2A, DUSP10, RTF1, DAZAP1, HBP1, AFF4, GRHL1, ERGIC2, WAC, POLK     0.010514

###### The enriched pathways for target genes of hsa-miR-150-3p, hsa-miR-4429, hsa-miR-4689 and hsa-miR-92a-3p.

  Pathway_ID                             Name                            Count                                                               Target genes                                                                  FDR
  ------------ -------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------- ----------
  hsa03018                         RNA degradation                        10                                        BTG2, CNOT6, CNOT7, DHX36, PAN3, PAPD5, POLS, TOB1, TOB2, XRN1                                       0.00254
  hsa04730                       Long-term depression                      8                                             GNA13, GNAI1, GRIA3, IGF1, IGF1R, ITPR1, MAPK1, NRAS                                            0.007796
  hsa04360                          Axon guidance                         12                                DCC, GNAI1, MAPK1, NRAS, NRP1, PAK7, PLXNC1, RGS3, ROBO2, ROCK1, SEMA3A, SEMA6D                              0.006358
  hsa04068                      FoxO signaling pathway                    12                                   AKT3, CPD, FOXO3, IGF1, IGF1R, KLF2, MAPK1, NLK, NRAS, PRKAA2, PTEN, SGK1                                 0.007496
  hsa05410                Hypertrophic cardiomyopathy (HCM)                9                                       ATP2A2, CACNA2D4, CACNG2, DAG1, IGF1, ITGA5, ITGAV, PRKAA2, TPM3                                      0.007272
  hsa05414                      Dilated cardiomyopathy                     9                                        ADCY3, ATP2A2, CACNA2D4, CACNG2, DAG1, IGF1, ITGA5, ITGAV, TPM3                                      0.011524
  hsa04150                      mTOR signaling pathway                     7                                                  AKT3, IGF1, MAPK1, PRKAA2, PTEN, TSC1, ULK1                                                0.012814
  hsa04611                       Platelet activation                      11                                ADCY3, AKT3, COL1A2, GNA13, GNAI1, ITPR1, MAPK1, PPP1R12A, RAP1A, RAP1B, ROCK1                               0.012208
  hsa05214                              Glioma                             7                                                  AKT3, CDK6, IGF1, IGF1R, MAPK1, NRAS, PTEN                                                 0.016841
  hsa04510                          Focal adhesion                        14                        AKT3, CAV2, COL1A2, IGF1, IGF1R, ITGA5, ITGAV, MAPK1, PAK7, PPP1R12A, PTEN, RAP1A, RAP1B, ROCK1                      0.02147
  hsa04151                    PI3K-Akt signaling pathway                  20     AKT3, CDK6, COL1A2, CREB5, FOXO3, IGF1, IGF1R, ITGA5, ITGAV, KITLG, MAPK1, MCL1, MYB, NRAS, PHLPPL, PPP2R3A, PRKAA2, PTEN, SGK1, TSC1   0.020308
  hsa05218                             Melanoma                            7                                                  AKT3, CDK6, IGF1, IGF1R, MAPK1, NRAS, PTEN                                                 0.022286
  hsa03015                    mRNA surveillance pathway                    8                                             DAZAP1, GSPT1, HBS1L, MSI2, NXT2, PNN, PPP2R3A, SMG7                                            0.024566
  hsa05412      Arrhythmogenic right ventricular cardiomyopathy (ARVC)     7                                              ATP2A2, CACNA2D4, CACNG2, CDH2, DAG1, ITGA5, ITGAV                                             0.024824

###### Distribution of study subjects and liver function tests.

                          BA                NC          P value
  ---------------- ----------------- ----------------- ----------
  Age (days)\*       70.30 ± 15.15     64.25 ± 10.33      0.32
  Male/Female            25/20             18/12          0.35
  Diagnosis type        III^1^                            N/A
  TB (μmol/L)       188.52 ± 100.36   158.62 ± 50.46      0.59
  DB (μmol/L)       150.45 ± 71.25    125.32 ± 35.33      0.51
  DB/TB               0.76 ± 0.45       0.74 ± 0.36       0.11
  AST (IU/L)        268.15 ± 220.40   225.50 ± 200.67     0.15
  ALT (IU/L)        135.10 ± 105.25   146.30 ± 135.25     0.55
  γ-GGT             766.35 ± 650.67   245.15 ± 210.42    \< 0.01

Type III biliary atresia refers to the discontinuity of both right and left hepatic ducts to the level of porta hepatis. Unfortunately, type III BA is common, accounting for \>90% of cases. \*at liver biopsy sample day.

BA: biliary atresia; NC: non-BA neonatal cholestasis infants; ALT: Alanine transaminase; AST: Aspartate transaminase; DB: Direct bilirubin; TB: Total bilirubin; γ-GGT: Gamma glutamyl transpeptidase.

###### Primers used for quantitative real-time PCR (qRT-PCR).

  miRNAs                Primer sequences
  ----------------- ------------------------
  hsa-miR-92a-3p     UAUUGCACUUGUCCCGGCCUGU
  hsa-miR-3911       UGUGUGGAUCCUGGAGGAGGC
  hsa-miR-4689       UUGAGGAGACAUGGUGGGGGCC
  hsa-miR-3196         CGGGGCGGCAGGGGCCU
  hsa-miR-4429        AAAAGCUGGGCUGAGAGGCG
  hsa-miR-150-3p     CUGGUACAGGCCUGGGGGACAG
  hsa-miR-642b-3p    AGACACAUUUGGAGAGGGACCC
  hsa-miR-1249       ACGCCCUUCCCCCCCUUCUUCA
  has-miR-1228        UCACACCUGCCUCGCCCCCC

[^1]: These authors contributed equally to this work.
